MFDS approves new ‘Olumiant Tab,’ rheumatoid arthritis treatment
The Ministry of Food and Drug Safety announced the ministry approved the Lilly Korea’s 2 products including ‘Olumiant Tab 2mg(generic name: baricitinib)’ and ‘Olumiant Tab 4mg(generic name: baricitinib)’ as a rheumatoid arthritis treatment on 11 December.
‘Olumiant Tab,’ an selective and reversi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
